Ozempic (semaglutide SC once-weekly) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 12 Diseases   138 Trials   138 Trials   3994 News 


«12...678910111213141516...3940»
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Safety Profile of Once-Weekly Subcutaneous Semaglutide in a Real-World Adult Population with T2D (Poster Halls B-C; [Board No. 797]) -  Apr 10, 2023 - Abstract #ADA2023ADA_1387;    
    A two-fold increase in level-2 hypoglycemia was associated with insulin use and microvasculopathy. No new safety concerns were observed with OW semaglutide in this large, diverse, RW population with T2D; the safety profile was in line with that of phase 3 trials of semaglutide.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
    Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo or Semaglutide Irrespective of Baseline Beta-Cell Function (Poster Halls B-C; [Board No. 771]) -  Apr 10, 2023 - Abstract #ADA2023ADA_1360;    
    Tirzepatide (TZP), a once-weekly GIP/GLP-1 receptor agonist, achieved significantly greater HbA1c and body weight (BW) reductions with all doses (5, 10, 15 mg) vs placebo (SURPASS-1 [S-1]) and semaglutide (SEMA) 1 mg (SURPASS-2 [S-2]) in randomized Phase 3 trials in people with type 2 diabetes controlled by diet and exercise (S-1) or metformin (S-2)...BW reductions were greater across Qs with all TZP doses (ranging from 6%-14%) than placebo (up to 2%) or SEMA (up to 7%). TZP was more efficacious than placebo or SEMA in reducing HbA1c and BW across a spectrum of pancreatic beta-cell function, notably achieving greater glycemic improvement in people with markers of diminished pancreatic beta cell function at baseline.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
    GLP-1 Receptor Agonists Dulaglutide and Semaglutide in Japanese Patients with Type 2 Diabetes (Poster Halls B-C; [Board No. 748]) -  Apr 10, 2023 - Abstract #ADA2023ADA_1334;    
    Gastrointestinal symptoms were observed in 13.2% of D and 46.3% of S (p<0.01). DTR-QoL scores related to pain and gastrointestinal symptoms were superior in D. This prospective trial demonstrated that S has more pronounced effects on glucose and BMI lowering, as well as a reduction in liver fat percentage and visceral fat area.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Semaglutide Increases the Proportion of People with T2D Achieving a Metabolic Composite Endpoint (Poster Halls B-C; [Board No. 746]) -  Apr 10, 2023 - Abstract #ADA2023ADA_1332;    
    The proportion of participants reaching the composite endpoint across all trials was 24% and 32% for 0.5 mg and 1.0 mg semaglutide, respectively, vs 11% for comparators (p<0.0001). The results indicate that OW semaglutide may assist with the co-management of T2D and cardiometabolic risk factors, which could reduce the risk of CVD in people with T2D.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk
    Effect of Coadministered s.c. Semaglutide and s.c. Cagrilintide on Glycemic Levels Measured by CGM (Ballroom 20D; [Board No. 54]) -  Apr 10, 2023 - Abstract #ADA2023ADA_97;    
    P2
    The results indicate that OW semaglutide may assist with the co-management of T2D and cardiometabolic risk factors, which could reduce the risk of CVD in people with T2D. In total, 92 adult participants with T2D (HbA1c 7.5-10.0%), on metformin
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk
    Efficacy and Safety of Coadministered s.c. Semaglutide and s.c. Cagrilintide in Type 2 Diabetes (Ballroom 20D; [Board No. 53]) -  Apr 10, 2023 - Abstract #ADA2023ADA_96;    
    P2
    In total, 92 adult participants with T2D (HbA1c 7.5-10.0%), on metformin In this phase 2 (NCT04982575), multicenter, double-blind trial, adults with T2D (HbA1c 7.5-10.0%) and BMI ?27 kg/m2 on metformin
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Trial initiation date, Trial primary completion date:  ADJUST-T1D: ADJUnct Semaglutide Treatment in Type 1 Diabetes (clinicaltrials.gov) -  Apr 7, 2023   
    P2,  N=80, Not yet recruiting, 
    In this phase 2 (NCT04982575), multicenter, double-blind trial, adults with T2D (HbA1c 7.5-10.0%) and BMI ?27 kg/m2 on metformin Initiation date: Jan 2023 --> Apr 2023 | Trial primary completion date: Nov 2024 --> Jul 2024
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly, Mounjaro (tirzepatide) / Eli Lilly
    Review, Journal:  Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes. (Pubmed Central) -  Apr 4, 2023   
    Because of the complementarity of action of the two incretins, tirzepatide showed better dose-dependent (5, 10 and 15mg) efficacy (greater reduction in HbA1c and body weight) than placebo, basal insulin or two GLP-1 analogues (dulaglutide and semaglutide) in the SURPASS program...Other original molecules have been built, including triple GIP/GLP-1/glucagon receptor agonists. The risk/benefit ratio will decide whether dual (or triple) receptor agonists should replace pure GLP-1 receptor agonists for the management of T2D in the near future, with a significant role in the pharmacotherapy of obesity.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide/NNC0480-0389 (NN9389) / Novo Nordisk, NNC0480-0389 / Novo Nordisk
    Trial completion, Combination therapy:  A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes (clinicaltrials.gov) -  Apr 3, 2023   
    P2,  N=500, Completed, 
    The risk/benefit ratio will decide whether dual (or triple) receptor agonists should replace pure GLP-1 receptor agonists for the management of T2D in the near future, with a significant role in the pharmacotherapy of obesity. Active, not recruiting --> Completed
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Retrospective data, Journal:  Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip. (Pubmed Central) -  Mar 30, 2023   
    Eight patients did not tolerate the dose of 1mg, and they therefore continued with 0.5mg of OWSema. Once weekly treatment with semaglutide and empagliflozine achieves a great reduction in HbA1c, and as such are safe for treatment of T2DM.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Trial primary completion date:  A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes (clinicaltrials.gov) -  Mar 30, 2023   
    P3,  N=332, Recruiting, 
    Once weekly treatment with semaglutide and empagliflozine achieves a great reduction in HbA1c, and as such are safe for treatment of T2DM. Trial primary completion date: Feb 2023 --> Sep 2023